iTeos Therapeutics and GSK announce development and commercialisation collaboration for EOS-448, an anti-TIGIT monoclonal antibody, enabling novel next-generation immuno-oncology combinations

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Pat Purcell
Meeting Engagement

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Suma Ramadas, PhD
Medical Affairs

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment